Insilico Therapeutics announced preliminary positive data from the first human Phase I clinical trial of ISM6331

Insilico Therapeutics released Phase I clinical data of the investigational oral pan-TEAD inhibitor ISM6331 at the ESMO Annual Meeting. As of August 14, 2026, the once-daily 130mg dose group achieved an objective response rate (ORR) of 40%, and the disease control rate (DCR) in the 30-130mg dose range was 68.2%.